GENFIT is a late-stage clinical biopharmaceutical company focused on the discovery and development of drug candidates and diagnostic solutions targeting metabolic and liver-related diseases. Co. is engaged in the field of nuclear receptor-based drug discovery. Co. is evaluating its primary drug candidate, elafibranor, as a potential treatment for primary biliary cholangitis. Co. is also conducting pre-clinical research, notably on NTZ, which could be repositioned for the treatment of liver fibrosis. The GNFT average annual return since 2019 is shown above.
The Average Annual Return on the GNFT average annual return since 2019 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GNFT average annual return since 2019 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GNFT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|